Peptides / Weight and metabolic

Synthetic analog · 29 amino acids · 4,231.6 Da

Survodutide

Not approvedBanned in sport

Survodutide is an experimental glucagon and GLP-1 receptor agonist, in phase 3 trials for obesity and MASH, a fatty liver disease, and not approved. Studies in people tested it for weight loss, liver fat and blood sugar, and tracked stomach side effects. PepBank shows 137 results on survodutide from 18 studies in people, and 35 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as BI 456906, BI-456906, BI456906

29 amino acids, from first to last3 changed amino acids

Evidence level: Large trials in people137 of 172 results come from studies in people, including randomized trials.

Results in people

137

80% of 172 results

Results in animals

33

19% of 172 results

Results in lab cells

2

1% of 172 results

From computer models

0

0% of 172 results

Overview

Survodutide at a glance

What it is	Synthetic analog, 29 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S0)
Studies	27 studies with results. 23 of them gave survodutide, with 172 results. 137 in people33 in animals2 in lab cells
Best study in people	Randomized controlled trial with 725 people (2026)
Clinical trials	35 registered: 10 active or planned, 3 with posted results
Community use	Weight loss, and interest in liver fat reduction (mostly discussed, not reported as used)

The science

What is survodutide?

Investigational lipidated glucagon analogue that activates glucagon and GLP-1 receptors. In phase 3 trials for obesity and MASH; not approved.

29

Amino acids in one chain

The history of survodutide

2022
The oldest paper on survodutide in PepBank is from 2022.
2023November
A registered trial of survodutide started (NCT06077864).

Survodutide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 29 amino acidsFrom the first amino acid to the last

H1XQGT5FTS−DY10S+KYL−D15−E+RAA+K20−DFI+KW25L−ESA

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Survodutide is a synthetic analog of 29 amino acids, with no ring, 3 changed amino acids.

Formula

C₁₉₂H₂₈₉N₄₇O₆₁

Molecular weight

4,231.6 g/mol

CAS number

2805997-46-8

Targets

Glucagon receptor (gene GCGR): agonistEvidence: primary literatureGlucagon-like peptide 1 receptor (gene GLP1R): agonistEvidence: primary literature

Development

Boehringer Ingelheim (licensed from Zealand Pharma). Highest phase: phase 3.

Identifiers

PubChem 171378821, ChEMBL CHEMBL5314776, UNII 2ALA66NS64, DrugBank DB18989, KEGG D12898, IUPHAR 13383

Full sequence, SMILES and InChIKey

Three-letter sequence
H-His-Ac4c-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys[N6-(Gly-Gly-Ser-Gly-Ser-Gly-gammaGlu-CO-(CH2)16-COOH)]-Trp-Leu-Glu-Ser-Ala-NH2

InChIKey
MEDXQFAHWBMVIM-PCLHIQTFSA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C7(CCC7)NC(=O)[C@H](CC8=CNC=N8)N

See charge, composition and 3D structure on the Scientific page

The evidence

What survodutide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people137 of 172 results come from studies in people, including randomized trials.

Weight and appetite

44 results · 38 in people · 6 animal

In adults with obesity, survodutide at up to 3.6 mg weekly reduced body weight more than placebo after 76 weeks. The New England journal of medicine, 2026

Top results

In adults with obesity, survodutide at up to 3.6 mg weekly reduced body weight more than placebo after 76 weeks. (The New England journal of medicine, 2026)
In mice, BI 456906 reduced food intake, which helped explain its stronger weight loss. (Molecular metabolism, 2022)
In mice, survodutide activated several brain regions that help control food intake. (Molecular metabolism, 2026)

Liver

29 results · 28 in people · 1 animal

In adults with MASH, more people improved on survodutide 2.4 mg (47%) than on placebo (14%). The New England journal of medicine, 2024

Top results

In adults with MASH, more people improved on survodutide 2.4 mg (47%) than on placebo (14%). (The New England journal of medicine, 2024)
In adults with MASH, about two thirds of survodutide's effect on MASH resolution was explained by weight loss. (Hepatology, 2026)
In a pooled analysis of trials in people with MASH, survodutide improved liver scarring more often than placebo. (Hepatology, 2025)

Blood sugar

30 results · 23 in people · 7 animal

In adults with overweight or obesity and normal glucose, survodutide did not significantly change HOMA-β compared with placebo. Diabetes, obesity & metabolism, 2026

Top results

In adults with overweight or obesity and normal glucose, survodutide did not significantly change HOMA-β compared with placebo. (Diabetes, obesity & metabolism, 2026)
In a pooled analysis of adult trials, survodutide lowered fasting glucagon levels more than placebo. (Diabetes, obesity & metabolism, 2025)
In adults with obesity and type 2 diabetes, survodutide 3.6 mg weekly lowered HbA1c more than placebo. (The New England journal of medicine, 2026)

Cholesterol and blood fats

2 results · 2 in people

In a pooled analysis of adult trials, survodutide modestly lowered total cholesterol. Diabetes, obesity & metabolism, 2025

Top results

In a pooled analysis of adult trials, survodutide modestly lowered total cholesterol. (Diabetes, obesity & metabolism, 2025)
In a pooled analysis of adult trials, survodutide modestly lowered triglycerides. (Diabetes, obesity & metabolism, 2025)

Heart and blood vessels

1 result · 1 in people

In a pooled analysis of adult trials, survodutide modestly lowered blood pressure. Diabetes, obesity & metabolism, 2025

Top results

In a pooled analysis of adult trials, survodutide modestly lowered blood pressure. (Diabetes, obesity & metabolism, 2025)

Survival and serious illness

1 result · 1 in people

In adults with obesity, no deaths were reported in the survodutide or placebo groups of this trial. The New England journal of medicine, 2026

Top results

In adults with obesity, no deaths were reported in the survodutide or placebo groups of this trial. (The New England journal of medicine, 2026)

All 27 survodutide studies by area Open the Scientific page

Key survodutide studies

Studies in people come first, then studies in animals and in the lab.

People
Survodutide Once Weekly for the Treatment of Adults with Obesity
le et al. 2026 · The New England journal of medicine · 725 people · cited by 10
7 results
People
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal et al. 2024 · The New England journal of medicine · 293 people · cited by 426
13 results
People
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
Wharton et al. 2026 · The New England journal of medicine · 251 people · cited by 0
8 results
People
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
Ekinci et al. 2026 · Diabetes, obesity & metabolism · 387 people · cited by 1
15 results
People
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH
Noureddin et al. 2026 · Hepatology (Baltimore, Md.) · 170 people · cited by 0
6 results

All 27 Survodutide studies

Survodutide clinical trials

ClinicalTrials.gov lists 35 trials of survodutide. 10 are active or planned, and 3 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Phase 3completed5,531 people

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Phase 3recruiting1,800 planned

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Phase 3recruiting1,590 planned

All 8 Survodutide trials

Status and safety

Is survodutide approved?

FDA

United States

Investigational

Investigational.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S0.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026). Banned in sport (WADA S0).

Laws and labels change, so check the regulator for the current status.

Survodutide side effects and safety

PepBank has 37 safety results from studies of survodutide. 37 of them come from studies in people.

Safety results from studies (37)

In adults with obesity, no deaths were reported in the survodutide or placebo groups of this trial. (The New England journal of medicine, 2026)
In adults with MASH, nausea was more common with survodutide (66%) than with placebo (23%). (The New England journal of medicine, 2024)
In adults with obesity and type 2 diabetes, stomach and bowel side effects were more common with survodutide 6.0 mg than with placebo. (The New England journal of medicine, 2026)
In Japanese men with overweight or obesity, some people on BI 456906 stopped dose increases because of side effects. No one on placebo did. (Diabetes, obesity & metabolism, 2023)
Side effects on survodutide occurred at similar rates in men, women and BMI subgroups. (Diabetes, obesity & metabolism, 2025)
In a pooled analysis of adult trials, survodutide caused more stomach and bowel side effects than placebo. (Diabetes, obesity & metabolism, 2025)
In adults with obesity or diabetes, survodutide 2.4 mg was linked to more side effects than placebo in pooled trials. (Indian journal of endocrinology and metabolism, 2025)
In four pooled trials, overall side effects were not significantly different between survodutide and placebo. (Proceedings, 2025)
With weekly doses over 28 weeks, drug-related side effects occurred in 82.4% and 87.5% of the two groups. (Journal of hepatology, 2024)
In a 6-week multiple-dose study, 10 of 80 people stopped BI 456906. (Diabetes, obesity & metabolism, 2023)
In adults with MASH, diarrhea was more common with survodutide (49%) than with placebo (23%). (The New England journal of medicine, 2024)
In adults with MASH, vomiting was more common with survodutide (41%) than with placebo (4%). (The New England journal of medicine, 2024)
In adults with MASH, serious side effects occurred in 8% on survodutide and 7% on placebo. (The New England journal of medicine, 2024)
In adults with obesity and type 2 diabetes, stomach and bowel side effects were more common with survodutide 3.6 mg than with placebo. (The New England journal of medicine, 2026)
In Japanese men with overweight or obesity, every person on BI 456906 had a drug-related side effect, compared with four on placebo. (Diabetes, obesity & metabolism, 2023)
In Japanese men with overweight or obesity, reduced appetite was the most common drug-related side effect of BI 456906. (Diabetes, obesity & metabolism, 2023)
In Japanese men on BI 456906, more people in the 4.8 mg weekly group stopped dose increases because of side effects. (Diabetes, obesity & metabolism, 2023)
In Japanese men with overweight or obesity, nine people on BI 456906 stopped dose increases because of reduced appetite. (Diabetes, obesity & metabolism, 2023)
In Japanese men with overweight or obesity, one person on BI 456906 stopped dose increases because of a rise in amylase. (Diabetes, obesity & metabolism, 2023)
In adults with obesity, stomach and gut symptoms were more common with survodutide up to 3.6 mg weekly than with placebo. (The New England journal of medicine, 2026)
In adults with obesity, stomach and gut symptoms were more common with survodutide up to 6.0 mg weekly than with placebo. (The New England journal of medicine, 2026)
Nausea was the most common stomach or bowel side effect of survodutide in all subgroups. (Diabetes, obesity & metabolism, 2025)
In a pooled analysis of adult trials, survodutide did not clearly cause more serious side effects than placebo. (Diabetes, obesity & metabolism, 2025)
In adults with obesity or diabetes, survodutide 3.6 mg was linked to more side effects than placebo in pooled trials. (Indian journal of endocrinology and metabolism, 2025)

See every safety result on the Scientific page

Doses studied (29 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
2.4 mg once weekly	Human	human	subcutaneous	48 weeks	Randomized trial in people	Sanyal 2024
4.8 mg once weekly	Human	human	subcutaneous	48 weeks	Randomized trial in people	Sanyal 2024
6.0 mg once weekly	Human	human	subcutaneous	48 weeks	Randomized trial in people	Sanyal 2024
up to 3.6 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized trial in people	le 2026
up to 6.0 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized trial in people	le 2026
3.6 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized trial in people	Wharton 2026
6.0 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized trial in people	Wharton 2026
3.6 mg or 6.0 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized trial in people · n = 725	le 2026
2.4, 4.8 or 6.0 mg once weekly	Human	human	subcutaneous	48 weeks	Randomized trial in people · n = 293	Sanyal 2024
4.8 mg once weekly (DG 2 maximum dose)	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 27	Yazawa 2023
1.8 mg once weekly (DG 1 maximum dose)	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 18	Yazawa 2023
2.4 mg twice weekly (DG 3 maximum dose)	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 18	Yazawa 2023
DG 2 and DG 3	Human	human	subcutaneous	1 week	Randomized trial in people	Yazawa 2023
0.6, 2.4, 3.6 or 4.8 mg once weekly	Human	human	subcutaneous	46 weeks	Randomized trial in people	le 2025
2.4 mg/week	Human	human	Not reported	Not reported	Systematic review of studies	Banerjee 2026
4.8-6 mg/week	Human	human	Not reported	Not reported	Systematic review of studies	Banerjee 2026
2.4 mg weekly	Human	human	subcutaneous	4-11 months	Systematic review of studies	Dutta 2025
3.6 mg weekly	Human	human	subcutaneous	4-11 months	Systematic review of studies	Dutta 2025
more than 2 mg/week	Human	human	injectable	Not reported	Systematic review of studies	Wan 2024
6 mg/week	Human	human	Not reported	Not reported	Systematic review of studies	Sun 2026
0.3 mg single dose	Human	human	subcutaneous	single dose	Trial in people without random groups · n = 41	Lawitz 2024
0.3 mg escalated to 6.0 mg once weekly	Human	human	subcutaneous	28 weeks	Trial in people without random groups · n = 41	Lawitz 2024
dosage schedule 1	Human	human	subcutaneous	6 weeks	Trial in people without random groups	Jungnik 2023
dosage schedule 7	Human	human	subcutaneous	16 weeks	Trial in people without random groups	Jungnik 2023
30 nmol/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Thomas 2024
100 nmol/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Thomas 2024
30 nmol/kg once daily	Animal	mouse	Not reported	Not reported	Study in live animals	Thomas 2024
10 and 20 nmol/kg once daily	Animal	mouse	Not reported	Not reported	Study in live animals	Thomas 2024
7.5 nmol/kg once daily	Animal	mouse	subcutaneous	10 weeks	Study in live animals	Hamilton 2026

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Survodutide is an investigational glucagon and GLP-1 drug in phase 3 trials. The one community source says reports of personal use are extremely rare. It lists trial-based doses of 0.3 to 6 mg once a week.

Reported routines and cautions

What people use it for

Weight loss, and interest in liver fat reduction (mostly discussed, not reported as used)S1

Reported regimens

Regimens that community sources report for Survodutide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Copying the phase 2/3 trial doses (reported as niche)	subcutaneous injectionfrom a very small number of research-chemical vendors	0.3 to 6 mg per dose	once weekly	46 to 48 weeks	single source; the source carries seller links	S1

Cautions

Product quality and identity are hard to verify from the few research-chemical vendors.S1
The wiki says self-treatment of liver disease is particularly risky. It says liver effects of the glucagon component need medical monitoring that self-experimenters lack.S1

Status notes

News dated 2026-10-01 calls survodutide investigational. It reports phase 3 SYNCHRONIZE-2 results in adults with obesity or overweight and type 2 diabetes, presented at a European diabetes meeting. The wiki says it is not FDA-approved for any indication.S3S1
Per a law-firm summary, FDA issued warning letters on 2024-12-17 to five companies that offer GLP-1 products, including survodutide. FDA determined that these products are unapproved new drugs.S2

Community sources

S1Survodutide: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S2FDA targets GLP-1 providers with warning letters (opens in a new tab)foley.com
S3Dual agonist survodutide delivers up to 13.1% weight loss in T2D (opens in a new tab)ajmc.com

Gaps

Almost no community use was found. The only community source is a wiki that summarizes Reddit and lists trial doses, not verified user reports. No reported side effects from community users were found. No forum posts with doses were found.

Questions and more

Ask a question about survodutide

The answer links to every study it uses.

What does the evidence say about survodutide?Is survodutide tested in people?Compare with Semaglutide Compare with Liraglutide

Sources

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about survodutide

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).